20350948

Source:http://linkedlifedata.com/resource/pubmed/id/20350948

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013162, umls-concept:C0026926, umls-concept:C0441655
pubmed:issue	6
pubmed:dateCreated	2010-5-18
pubmed:abstractText	Aerobic (5-day-old cultures) and nonreplicating (dormant) Mycobacterium tuberculosis (5-, 12-, and 19-day-old cultures) bacteria were treated with rifampin (R), moxifloxacin (MX), metronidazole (MZ), amikacin (AK), or capreomycin (CP) for 7, 14, and 21 days. R-MX-MZ-AK and R-MX-MZ-CP killed both aerobic and dormant bacilli in 21 days, as shown by lack of regrowth in solid and liquid media. R-MX-MZ-AK and R-MX-MZ-CP also caused a strong decrease of nonreplicating bacilli in 7 days in a cell-based dormancy model.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0315061
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Amikacin, http://linkedlifedata.com/resource/pubmed/chemical/Antitubercular Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aza Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Capreomycin, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Metronidazole, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines, http://linkedlifedata.com/resource/pubmed/chemical/Rifampin, http://linkedlifedata.com/resource/pubmed/chemical/moxifloxacin
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1098-6596
pubmed:author	pubmed-author:FattoriniLanfrancoL, pubmed-author:FilippiniPerlaP, pubmed-author:IonaElisabettaE, pubmed-author:NeyrollesOlivierO, pubmed-author:PeyronPascaleP, pubmed-author:PiccaroGiovanniG
pubmed:issnType	Electronic
pubmed:volume	54
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2712-5
pubmed:dateRevised	2011-3-3
pubmed:meshHeading	pubmed-meshheading:20350948-3T3 Cells, pubmed-meshheading:20350948-Adipocytes, pubmed-meshheading:20350948-Amikacin, pubmed-meshheading:20350948-Animals, pubmed-meshheading:20350948-Antitubercular Agents, pubmed-meshheading:20350948-Aza Compounds, pubmed-meshheading:20350948-Capreomycin, pubmed-meshheading:20350948-Colony Count, Microbial, pubmed-meshheading:20350948-Drug Combinations, pubmed-meshheading:20350948-Drug Resistance, Bacterial, pubmed-meshheading:20350948-Humans, pubmed-meshheading:20350948-Latent Tuberculosis, pubmed-meshheading:20350948-Metronidazole, pubmed-meshheading:20350948-Mice, pubmed-meshheading:20350948-Microbial Sensitivity Tests, pubmed-meshheading:20350948-Models, Biological, pubmed-meshheading:20350948-Mycobacterium tuberculosis, pubmed-meshheading:20350948-Quinolines, pubmed-meshheading:20350948-Rifampin
pubmed:year	2010
pubmed:articleTitle	Activity of drug combinations against dormant Mycobacterium tuberculosis.
pubmed:affiliation	Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanità, Viale Regina Elena, Rome, Italy.
pubmed:publicationType	Journal Article, In Vitro, Research Support, Non-U.S. Gov't